Optimizing Care of Patients with Rheumatoid Arthritis - CME Outfitters
Optimizing Care of Patients with Rheumatoid Arthritis - CME Outfitters
Optimizing Care of Patients with Rheumatoid Arthritis - CME Outfitters
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>INFORMATION FOR PARTICIPANTSStatement <strong>of</strong> NeedNew and emerging strategies for diagnosing rheumatoid arthritis (RA) are continually being explored in research, and many showpromising and effective application for real-world clinical practice. To facilitate diagnosis and therefore, early treatment <strong>of</strong> thedisease, clinicians should be aware <strong>of</strong> validated assessment tools, which can be effectively applied in real-world practice settings.Further, monitoring <strong>of</strong> disease activity and progression using an outcome measure is a valuable and important practice in theoptimization <strong>of</strong> treatment for patients <strong>with</strong> RA. Current guidelines advocate for the early and sustained use <strong>of</strong> DMARD therapyin RA. However, clinicians require a more thorough understanding <strong>of</strong> different strategies in selecting appropriate combinationDMARD therapy for each patient, which will ultimately increase chances <strong>of</strong> remission.(1)In this <strong>CME</strong> <strong>Outfitters</strong> Live and On Demand activity, expert faculty will comprehensively analyze and discuss strategies for earlydiagnosis, early and sustained DMARD therapy, and measurement-based care that will help clinicians improve care <strong>of</strong> theirpatients <strong>with</strong> RA.1Dale J, Alcorn N, Capell H, Madhok R. Combination Therapy for <strong>Rheumatoid</strong> <strong>Arthritis</strong>: Methotrexate and Sulfasalazine Together or With Other DMARDs. Nat Clin Pract Rheumatol <strong>CME</strong>2007;3:450-458. http://www.medscape.org/viewarticle/560135 Accessed March 11, 2011.Activity GoalUse <strong>of</strong> diagnostic strategies and measurement-based care tools and principles to optimize management and improve quality <strong>of</strong>life for patients <strong>with</strong> rheumatoid arthritis.Learning ObjectivesAt the end <strong>of</strong> this <strong>CME</strong>/CE activity, participants should be able to:• Apply new diagnostic strategies for rheumatoid arthritis to facilitate early diagnosis <strong>of</strong> the disease.• Utilize validated outcome measures to monitor disease activity and progression and ultimately optimize therapy for individualpatients <strong>with</strong> RA.• Integrate guidelines and strategies for combination DMARD therapy to facilitate more appropriate DMARD selections forpatient therapy.The following learning objectives pertain only to those requesting CNE credit:• Identify the purpose and uses <strong>of</strong> new diagnostic strategies for rheumatoid arthritis.• Name disease outcome measures used to monitor disease activity and progression in patients <strong>with</strong> rheumatoid arthritis.• Recognize guidelines and distinguish among currently available strategies for combination DMARD therapy.Target AudiencePhysicians, physician assistants, nurses, nurse practitioners, pharmacists, and other health care pr<strong>of</strong>essionals <strong>with</strong> an interest inrheumatoid arthritis.Financial SupportSupported by educational grants from Pfizer Inc. and Abbott Laboratories.Additional support has been provided by <strong>CME</strong> <strong>Outfitters</strong>, LLC.2
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>Allan Gib<strong>of</strong>sky, MD, JD, FACP, FCLMDr. Gib<strong>of</strong>sky is Pr<strong>of</strong>essor <strong>of</strong> Medicine and Public Health at Weill Medical College <strong>of</strong> Cornell University and Adjunct Pr<strong>of</strong>essor <strong>of</strong> Lawat Fordham University School <strong>of</strong> Law. He is an Attending Physician and Rheumatologist at The New York Presbyterian Hospitaland Hospital for Special Surgery, where he is Co-Director <strong>of</strong> the Center for Inflammatory <strong>Arthritis</strong> and Biologic Therapy.Dr. Gib<strong>of</strong>sky received his undergraduate degree from Brooklyn College <strong>of</strong> the City University <strong>of</strong> New York, his MD from WeillMedical College <strong>of</strong> Cornell University, and his law degree from Fordham University. He did his internship in Pathology, followedby a residency in Medicine at New York Hospital. He completed a fellowship in Rheumatology/Immunology jointly at Hospital forSpecial Surgery and at The Rockefeller University. Dr. Gib<strong>of</strong>sky has authored or co-authored numerous papers and text chaptersprimarily on the immunogenetics <strong>of</strong> rheumatic diseases and legal aspects <strong>of</strong> medical practice. He is known for his work onmechanisms <strong>of</strong> host-microbe interactions in rheumatology and, in particular, for his basic and clinical studies on rheumatic feveras well as for his work on therapeutic strategies in the treatment <strong>of</strong> inflammatory rheumatic diseases.Currently Secretary-Treasurer <strong>of</strong> The New York Rheumatism Association, Dr. Gib<strong>of</strong>sky is past-Chair <strong>of</strong> the Medical & ScientificCommittee <strong>of</strong> the New York Chapter <strong>of</strong> The <strong>Arthritis</strong> Foundation and received their Physicians’ Leadership Award. He also servedas a member <strong>of</strong> the local and national <strong>Arthritis</strong> Foundation Board <strong>of</strong> Trustees, and was Chair for Pr<strong>of</strong>essional Education. Dr.Gib<strong>of</strong>sky has participated in numerous pr<strong>of</strong>essional and public education programs, nationally and internationally. He is a pastpresident <strong>of</strong> the American College <strong>of</strong> Legal Medicine, and is past Chair <strong>of</strong> the American Board <strong>of</strong> Legal Medicine. In 2002, Dr.Gib<strong>of</strong>sky served as President <strong>of</strong> The American College <strong>of</strong> Rheumatology.Dr. Gib<strong>of</strong>sky is a Jonas Salk Scholar <strong>of</strong> the City University and, in 1997, he was named Alumnus <strong>of</strong> the Year by Brooklyn College.William F.C. Rigby, MDDr. Rigby received his medical degree from Harvard Medical School in Boston, Massachusetts. He completed an internshipin internal medicine at New England Deaconess Hospital in Boston and a residency in internal medicine at Mary HitchcockMemorial Hospital in Hanover, New Hampshire. Dr. Rigby is Pr<strong>of</strong>essor <strong>of</strong> Medicine, Microbiology, and Immunology in the Division<strong>of</strong> Rheumatology at Dartmouth Medical School and is the Staff Rheumatologist at Dartmouth-Hitchcock Medical Center inLebanon, New Hampshire. He became the Vice-Chairman <strong>of</strong> Academic Affairs in the Department <strong>of</strong> Medicine in 2008.Dr. Rigby is interested in novel pathways that regulate the expression <strong>of</strong> TNF and CD40 ligand (CD154). The author <strong>of</strong> numerouspeer-reviewed publications, Dr. Rigby has been a principal investigator in many clinical trials related to the treatment <strong>of</strong>rheumatoid arthritis, <strong>with</strong> a particular interest in the immunomodulatory effects <strong>of</strong> biologic agents.Disclosure <strong>of</strong> Relevant Financial Relationships <strong>with</strong> Commercial InterestsUSF Health and <strong>CME</strong> <strong>Outfitters</strong>, LLC, adhere to the AC<strong>CME</strong> Standards, as well as those <strong>of</strong> the ACPE, APA, and ANCC, regardingcommercial support <strong>of</strong> continuing medical education. It is the policy <strong>of</strong> USF Health and <strong>CME</strong> <strong>Outfitters</strong>, LLC, that the faculty andplanning committee disclose real or apparent conflicts <strong>of</strong> interest relating to the topics <strong>of</strong> this educational activity, that relevantconflict(s) <strong>of</strong> interest are resolved, and also that speakers will disclose any unlabeled/unapproved use <strong>of</strong> drug(s) or device(s)during their presentation.A conflict <strong>of</strong> interest is created when individuals in a position to control the content <strong>of</strong> <strong>CME</strong> have a relevant financial relationship<strong>with</strong> a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty,intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.USF Health and <strong>CME</strong> <strong>Outfitters</strong> will identify, review, and resolve all conflicts <strong>of</strong> interest that speakers, authors or planners discloseprior to an educational activity being delivered to learners. Disclosure <strong>of</strong> a relationship is not intended to suggest or condonebias in any presentation but is made to provide participants <strong>with</strong> information that might be <strong>of</strong> potential importance to theirevaluation <strong>of</strong> a presentation.Relevant financial relationships exist between the following individuals and commercial interests:Dr. Calabrese has disclosed that he serves on the speakers bureau <strong>of</strong> Amgen Inc.; Bristol-Myers Squibb; Centocor Ortho BiotechInc.; Genentech, Inc.; and H<strong>of</strong>fmann-La Roche Inc. He serves as a consultant to Bristol-Myers Squibb; Centocor Ortho Biotech Inc.;Genentech, Inc.; Pfizer Inc.; and H<strong>of</strong>fmann-La Roche Inc.4
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>Dr. Gib<strong>of</strong>sky has disclosed that he serves on the speakers bureaus <strong>of</strong> Abbott Laboratories; Amgen Inc.; Pfizer Inc.; H<strong>of</strong>fmann-LaRoche Inc.; and UCB, Inc. He serves as a consultant to Abbott Laboratories; Amgen Inc.; Pfizer Inc.; H<strong>of</strong>fmann-La Roche Inc.; andUCB, Inc. He is a stock shareholder <strong>of</strong> Abbott Laboratories; Amgen Inc.; Bristol-Myers Squibb; Johnson & Johnson PharmaceuticalResearch & Development, L.L.C.; and Pfizer Inc.Dr. Rigby has disclosed that he receives grants/research support from, and serves on the speakers bureau <strong>of</strong> H<strong>of</strong>fmann-La RocheInc. He serves as a consultant to H<strong>of</strong>fmann-La Roche Inc. and UCB, Inc.Disclosures were obtained from the planning committee members and are on file in the USF Health Office <strong>of</strong> ContinuingPr<strong>of</strong>essional Development (OCPD) for review. Disclosures were obtained from the USF Health OCPD staff: Nothing to Disclose.Ruth Cody, BSN, RN-BC (Content/Peer Reviewer) has no disclosures to report.Tony Graham, MD (Content/Peer Reviewer) has no disclosures to report.Nancy Jennings, MSN, MBA, MHA, RNC (Content/Peer Reviewer) has no disclosures to report.Sharon Tord<strong>of</strong>f, C<strong>CME</strong>P (planning committee) has no disclosures to report.Christina Ansted, MPH (planning committee) has no disclosures to report.Unlabeled Use DisclosureFaculty <strong>of</strong> this <strong>CME</strong>/CE activity may include discussions <strong>of</strong> products or devices that are not currently labeled for use by theFDA. The faculty have been informed <strong>of</strong> their responsibility to disclose to the audience if they will be discussing <strong>of</strong>f-label orinvestigational uses (any uses not approved by the FDA) <strong>of</strong> products or devices.USF Health, <strong>CME</strong> <strong>Outfitters</strong>, LLC, the faculty, Forest Research Institute, Inc., Lilly USA, LLC, and Pfizer Inc. do not endorse the use<strong>of</strong> any product outside <strong>of</strong> the FDA labeled indications. Medical pr<strong>of</strong>essionals should not utilize the procedures, products, ordiagnosis techniques discussed during this activity <strong>with</strong>out evaluation <strong>of</strong> their patient for contraindications or dangers <strong>of</strong> use.Equal Opportunity Statement: Events, activities, programs and facilities <strong>of</strong> the University <strong>of</strong> South Florida are available to all<strong>with</strong>out regard to race, color, marital status, gender, sexual orientation, religion, national origin, disability, age, Vietnam or disabledveteran status as provided by law and in accordance <strong>with</strong> the university’s respect for personal dignity.Activity SlidesThe slides that are presented in this activity are available for download and printout at the <strong>CME</strong> <strong>Outfitters</strong> website:www.cmeoutfitters.com. Activity slides may also be obtained via fax or email by calling 877.<strong>CME</strong>.PROS.5
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>Abbreviation List4S Joint swelling #44T Joint tenderness #4LDAMCPSLow disease activityMetacarpophalangeal jointsABAACPAAbataceptAnti-citrullinated protein/peptideantibodiesMDHAQMTXMultidimensional Health AssessmentQuestionnaireMethotrexateACRAmerican College <strong>of</strong> RheumatologyPCPPrimary care physicianACR20American College <strong>of</strong> Rheumatologycriteria, 20% responseANTI-IL6 Anti-interleukin 6BeSTCBCBehandelstrategieen voor ReumatoideArtritis (Behandel-Strategieën trial)Complete blood countPIPSRARADAIRAPID3Proximal interphalangeal joint<strong>Rheumatoid</strong> arthritis<strong>Rheumatoid</strong> <strong>Arthritis</strong> Disease ActivityIndexRoutine Assessment <strong>of</strong> Patient IndexData 3CCPCyclic citrullinated peptidesRF<strong>Rheumatoid</strong> factorCDAIClinical Disease Activity IndexRCTRandomized, controlled trialCRPC-reactive proteinRTXRituximabDANBIODanish nationwide voluntaryrheumatological database <strong>of</strong> biologicaltreatmentsSSDAIJoint swelling (as in RA)Simplified Disease Activity IndexDASDisease Activity ScoreSHSSharp-van der Heijde ScoreDAS28Disease Activity Score, 28-joint countSSZSulfasalazineDAS44Disease Activity Score, 44-joint countSWEFOTSwedish pharmacotherapyDMARDDisease-modifying antirheumatic drugTJoint tenderness (as in RA)ESRErythrocyte sedimentation rateT2TTreat to targetEULAREuropean League Against RheumatismTCZTocilizumabGASGlobal <strong>Arthritis</strong> ScoreTNFTumor necrosis factorGOLHAQHCQIFXGolimumabHealth Assessment QuestionnaireHydroxychloroquineInfliximabTNF-IRTSHUAInadequate response to anti-TNFinhibitorsThyroid stimulating hormoneUrinalysis6
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>8
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>10
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>11
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>12
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>Suboptimal RA Outcomes<strong>with</strong> Regular TreatmentSONORA Treatment in 4 large US community rheumatologypractices: 88% DMARD, 10% Biologic/DMARD Community practice results compared <strong>with</strong> resultsin clinical trialsClinical StudiesOutcomes: Clinical(2-year data) PracticesMTX +MTX AdalimumabACR 20 41 %ACR 50 24 % 43 59ACR 70 7 % 28 47Weisman MH, et al. Presented at the European Congress <strong>of</strong> Rheumatology (EULAR)annual meeting. Berlin, Germany; July 9-12, 2004. Abstract OP0042.13
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>14
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>15
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>16
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>17
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>Clinical Connections Treat early Set a precise goal or target for treatment Integrate continuous measurement <strong>of</strong> diseaseactivity<strong>with</strong> validated instruments Adjusting treatment based on the assessment<strong>of</strong> disease activity, combined <strong>with</strong> clinicaljudgment Use <strong>of</strong> ACR/EULAR criteria should be limitedto target populations <strong>with</strong> no other explanationfor their synovitis ACR/EULAR criteria are not designed as areferral tool for PCPs18
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>19
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>21
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>BibliographyAletaha D, Neogi T, Silman AJ, et al. 2010 <strong>Rheumatoid</strong> arthritis classification criteria: an American College <strong>of</strong> Rheumatology/European League Against Rheumatism collaborative initiative. <strong>Arthritis</strong> Rheum. 2010;62:2569-2581. PMID: 20872595.Alves C, Luime J, Van Zeben J, et al. The ACR/EULAR 2010 criteria as well as other predictive algorithms for rheumatoid arthritisshow good diagnostic performance. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):1775. No PMID.Bakker MF, et al. Low-dose prednisone inclusion into a MTX-based tight control strategy for early rheumatoid arthritis: bettercontrol <strong>of</strong> disease and erosive joint damage. Results from the double-blind randomized CAMERA-II trial [abstract no. OP0138,presented at EULAR 2011]. Ann Rheum Dis. 2011;70(Suppl 3):114.Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment <strong>of</strong> rheumatoid arthritis: efficacy and feasibility.Ann Rheum Dis. 2007;66(Suppl 3):iii56-iii60. PMID: 17934098.Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial <strong>of</strong>combination therapy <strong>with</strong> adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients <strong>with</strong> early,aggressive rheumatoid arthritis who had not had previous methotrexate treatment. <strong>Arthritis</strong> Rheum. 2006;54(1):26-37. PMID:16385520.Britsemmer K, Ursum J, Van Schaardenburg D. Similar performance <strong>of</strong> new and old criteria for rheumatoid arthritis in an earlyarthritis cohort in Amsterdam. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):85. No PMID.Bykerk VP, Boire G, Haraoui B, et al. The revised 2010 ACR/EULAR diagnostic criteria for rheumatoid arthritis identify many morepatients who are eligible for treatment and for clinical trials. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):659. No PMID.Call S, et al. Presented at the 2007 American College <strong>of</strong> Rheumatology Annual Scientific Meeting; Boston, MA. Abstract No. 425.Chitale S, Goodson NJ, Sharpley D, Thompson R, Moots R, Estrach C. New 2010 ACR-EULAR rheumatoid arthritis classificationcriteria are highly sensitive in patients <strong>with</strong> early rheumatoid arthritis. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):1763. No PMID.Cohen SB, Emery P, Greenwald MW, et al; for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti–tumornecrosis factor therapy: results <strong>of</strong> a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primaryefficacy and safety at twenty-four weeks. <strong>Arthritis</strong> Rheum. 2006;54(9):2793-2806. PMID: 16947627.Cush JJ. Presented at the 2005 American College <strong>of</strong> Rheumatology Annual Scientific Meeting; 2005 Nov 12 – 17; San Diego, CA.Abstract No. 1854.de Wit MP, Smolen JS, Gossec L, van der Heijde DM. Treating rheumatoid arthritis to target: the patient version <strong>of</strong> the internationalrecommendations. Ann Rheum Dis. 2011;70(6):891-895. PMID: 21478190.Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition <strong>with</strong> tocilizumab improves treatment outcomes in patients <strong>with</strong>rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomisedplacebo-controlled trial [erratum, Ann Rheum Dis. 2009;68(2):296]. Ann Rheum Dis. 2008;67(11):1516-1523. PMID: 18625622.Fautrel B, Rincheval N, Combe BG, Dougados M; for the ESPOIR Scientific Committee. Level <strong>of</strong> agreement <strong>of</strong> 1987 ACR and 2010ACR/EULAR classification criteria: an analysis based on the ESPOIR cohort data. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):1760.Fransen J, Langenegger T, Michel BA, Stucki G. Feasibility and validity <strong>of</strong> the RADAI, a self-administered rheumatoid arthritisdisease activity index. Rheumatology (Oxford). 2000;39(3):321-327. PMID: 10788543.Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. NEngl J Med. 2005;353(11):1114-1123.22
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>BibliographyGoekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes <strong>of</strong> four different treatmentstrategies in patients <strong>with</strong> early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. <strong>Arthritis</strong> Rheum.2005;52(11):3381-3390. PMID: 16258899.Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, et al. Clinical outcomes <strong>of</strong> four different treatment strategies in patients <strong>with</strong>recent-onset rheumatoid arthritis: 5-years results <strong>of</strong> the BeST-study [abstract no. 1996, presented at ACR 2008]. Ann Rheum Dis.2008;67(Suppl II):187. No PMID.Kolfenbach JR, Derber L, Deane KD. Application <strong>of</strong> the New ACR/EULAR classification criteria for rheumatoid arthritis to at-riskpopulations may identify RA prior to clinical presentation. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):658. No PMID.Mäkinen H, Hannonen P, Sokka T. Definitions <strong>of</strong> remission for rheumatoid arthritis and review <strong>of</strong> selected clinical cohorts andrandomised clinical trials for the rate <strong>of</strong> remission. Clin Exp Rheumatol. 2006;24(6 Suppl 43):S22-S28. PMID: 17083758.Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment <strong>of</strong>rheumatoid arthritis after the failure <strong>of</strong> a tumour necrosis factor inhibitor: a systematic review and economic evaluation. HealthTechnol Assess. 2011;15(14):1-278. PMID: 21439251.Mjaavatten MD, Van Der Heijde DM, Uhlig T, et al. The 2010 ACR/EULAR criteria for rheumatoid arthritis perform well in prediction<strong>of</strong> clinical RA diagnosis at 6 months in very early arthritis patients: longitudinal data from the NOR-VEAC cohort. <strong>Arthritis</strong> Rheum.2010;62(Suppl 10):1774. No PMID.Østergaard M, Unkerskov J, Krogh NS, et al. Poor remission rates but long drug survival in rheumatoid arthritis patients treated<strong>with</strong> infliximab or etanercept – results from the nationwide Danish “DANBIO” database. Presented at the European LeagueAgainst Rheumatism Annual Meeting; June 8-11, 2005; Vienna, Austria. Abstract No. OP0011. http://www.abstracts2view.com/eular/search.php?search=do&intMaxHits=10&where[]=&andornot[]=&query=OP0011. Accessed August 1, 2011.Pincus T, Yazici Y, Bergman M. Development <strong>of</strong> a multi-dimensional health assessment questionnaire (MDHAQ) for theinfrastructure <strong>of</strong> standard clinical care. Clin Exp Rheumatol. 2005;23(Suppl 39):S19-S28. PMID: 16273781.Smolen JS, Aletaha D, Bijlsma JW, et al; for the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations<strong>of</strong> an international task force. Ann Rheum Dis. 2010;69(4):631-637. PMID: 20215140.Smolen JS, Kay J, Doyle MK, et al.; for the GO-AFTER study investigators. Golimumab in patients <strong>with</strong> active rheumatoid arthritisafter treatment <strong>with</strong> tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind,placebo-controlled, phase III trial. Lancet. 2009;374(9685):210-221. PMID: 19560810.van der Linden MPM, Knevel R, Huizinga TWJ, Van Der Helm-Van Mil AHM. Classification <strong>of</strong> rheumatoid arthritis: comparison <strong>of</strong>the 1987 ACR and 2010 ACR/EULAR criteria. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):1744. No PMID.van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition <strong>of</strong> infliximab compared <strong>with</strong> addition <strong>of</strong> sulfasalazine andhydroxychloroquine to methotrexate in patients <strong>with</strong> early rheumatoid arthritis (SWEFOT trial): 1-year results <strong>of</strong> a randomisedtrial. Lancet. 2009;374(9688):459-466. PMID: 19665644.Yazici Y. Monitoring response to treatment in rheumatoid arthritis--which tool is best suited for routine “real world” care? BullNYU Hosp Jt Dis. 2007;65(Suppl 1):S25-S28. PMID: 17708742.23
<strong>Optimizing</strong> <strong>Care</strong> <strong>of</strong> <strong>Patients</strong> <strong>with</strong> <strong>Rheumatoid</strong> <strong>Arthritis</strong>: A Focus on Diagnosis, Combination Therapy, and Outcomes-Based <strong>Care</strong>Slide: “Selected Clinical Measurement Tools”Supplemental Bibliography1. Cush JJ. Presented at the 2005 American College <strong>of</strong> Rheumatology Annual Scientific Meeting; 2005 Nov 12 – 17; San Diego, CA.Abstract No. 1854.2. Mäkinen H, Hannonen P, Sokka T. Definitions <strong>of</strong> remission for rheumatoid arthritis and review <strong>of</strong> selected clinical cohorts andrandomised clinical trials for the rate <strong>of</strong> remission. Clin Exp Rheumatol. 2006;24(6 Suppl 43):S22-S28. PMID: 17083758.3. Yazici Y. Monitoring response to treatment in rheumatoid arthritis--which tool is best suited for routine “real world” care? BullNYU Hosp Jt Dis. 2007;65(Suppl 1):S25-S28. PMID: 17708742.4. Call S, et al. Presented at: 2007 ACR Annual Scientific Meeting. Boston, MA. Abstract 425.5. Fransen J, Langenegger T, Michel BA, Stucki G. Feasibility and validity <strong>of</strong> the RADAI, a self-administered rheumatoid arthritisdisease activity index. Rheumatology (Oxford). 2000;39(3):321-327. PMID: 10788543.6. Pincus T, Yazici Y, Bergman M. Development <strong>of</strong> a multi-dimensional health assessment questionnaire (MDHAQ) for theinfrastructure <strong>of</strong> standard clinical care. Clin Exp Rheumatol. 2005;23(Suppl 39):S19-S28. PMID: 16273781.Slide: “2010 Classification: Validity”1. Chitale S, Goodson NJ, Sharpley D, Thompson R, Moots R, Estrach C. New 2010 ACR-EULAR rheumatoid arthritis classificationcriteria are highly sensitive in patients <strong>with</strong> early rheumatoid arthritis. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):1763. No PMID.2. Fautrel B, Rincheval N, Combe BG, Dougados M; for the ESPOIR Scientific Committee. Level <strong>of</strong> agreement <strong>of</strong> 1987 ACR and 2010ACR/EULAR classification criteria: an analysis based on the ESPOIR cohort data. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):1760.3. van der Linden MPM, Knevel R, Huizinga TWJ, Van Der Helm-Van Mil AHM. Classification <strong>of</strong> rheumatoid arthritis: comparison <strong>of</strong>the 1987 ACR and 2010 ACR/EULAR criteria. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):1744. No PMID.4. Mjaavatten MD, Van Der Heijde DM, Uhlig T, et al. The 2010 ACR/EULAR criteria for rheumatoid arthritis perform well inprediction <strong>of</strong> clinical RA diagnosis at 6 months in very early arthritis patients: longitudinal data from the NOR-VEAC cohort.<strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):1774. No PMID.5. Alves C, Luime J, Van Zeben J, et al. The ACR/EULAR 2010 criteria as well as other predictive algorithms for rheumatoid arthritisshow good diagnostic performance. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):1775. No PMID.6. Bykerk VP, Boire G, Haraoui B, et al. The revised 2010 ACR/EULAR diagnostic criteria for rheumatoid arthritis identify many morepatients who are eligible for treatment and for clinical trials. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):659. No PMID.7. Britsemmer K, Ursum J, Van Schaardenburg D. Similar performance <strong>of</strong> new and old criteria for rheumatoid arthritis in an earlyarthritis cohort in Amsterdam. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):85. No PMID.8. Kolfenbach JR, Derber L, Deane KD. Application <strong>of</strong> the New ACR/EULAR classification criteria for rheumatoid arthritis to at-riskpopulations may identify RA prior to clinical presentation. <strong>Arthritis</strong> Rheum. 2010;62(Suppl 10):658. No PMID.24
Change language